U.S. market Closed. Opens in 17 hours 3 minutes

AXGN | AxoGen, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 13.78 - 14.50
52 Week Range 3.45 - 14.50
Beta 1.08
Implied Volatility 55.03%
IV Rank 13.03%
Day's Volume 418,044
Average Volume 433,772
Shares Outstanding 43,829,800
Market Cap 626,327,842
Sector Healthcare
Industry Medical - Devices
IPO Date 1986-12-17
Valuation
Profitability
Growth
Health
P/E Ratio -36.64
Forward P/E Ratio N/A
EPS -0.39
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 426
Country USA
Website AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
*Chart delayed
Analyzing fundamentals for AXGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see AXGN Fundamentals page.

Watching at AXGN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AXGN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙